Investor Summary
Fund Strategy
FUND PERFORMANCE AS OF 31st December 2025
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 14% | 1% | 0% |
| 2024 |
|---|
| 39.0% |
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 14% | 1% | 0% |
| 2024 |
|---|
| 39.0% |
Long Cast Advisers delivered 1% net returns in Q4 2025 but finished the year flat, underperforming after a decade of strong results that generated 14% annualized returns since inception. The concentrated portfolio focuses on small and micro-cap companies held for multiple years, with top five positions representing 62% of assets. Key contributors included MAMA, PESI, and PDEX, while RSSS and MTRX detracted from performance. The manager made significant new investments in healthcare-focused companies CCRN and NRC, betting on operational turnarounds and margin expansion opportunities. CCRN offers a nurse staffing play with 40% of market cap in cash following a failed acquisition, while NRC provides exposure to healthcare consulting with historically strong margins. The portfolio reflects a value-oriented approach targeting companies with strong balance sheets, low valuations, and potential catalysts. Despite current year challenges, the manager maintains conviction in the long-term strategy of patient capital deployment in well-researched small company opportunities, emphasizing the importance of concentration and fundamental analysis in generating superior returns.
Long Cast Advisers focuses on concentrated investments in well-researched small and micro-cap companies held for multiple years, targeting 15% annualized returns through patient capital deployment in undervalued businesses with strong fundamentals.
Manager remains committed to building durable business based on repeatable investment process and intelligent capital allocation, maintaining long-term focus on small company investing despite current year's flat performance.
| Date | Letter | Tickers | Keywords | Pitches | Quick Takes |
|---|---|---|---|---|---|
| Jan 24 2026 | 2025 Q4 | CCRD, CCRN, EEFT, LSYN, MAMA, MTRX, NRC, PDEX, PESI, QRHC, RELL, RSSS | healthcare, Owner-Operator, small caps, Staffing, value |
CCRN NRC MTRX RSSS |
Long Cast delivered flat 2025 returns despite strong Q4, maintaining concentrated small-cap strategy that has generated 14% annualized returns since inception. New healthcare investments in CCRN and NRC reflect value approach targeting companies with strong balance sheets and operational turnaround potential. Manager remains committed to patient capital deployment in well-researched micro and small-cap opportunities. |
| Nov 24 2025 | 2025 Q3 | MAMA, MTRX, PDEX, PESI, QRHC, RSSS | concentrated, healthcare, Manufacturing, Publishing, small caps, value |
PDEX MTRX RSSS PESI QRHC |
Long Cast delivered 4% net returns in 3Q25 but trails indices year-to-date despite 14% CAGR since inception. The concentrated small-cap value strategy focuses on niche companies with capable management, holding 10% cash amid uncertainty. Key holdings PDEX and RSSS offer compelling value at depressed prices with catalysts ahead, while avoiding speculative index components. |
| Aug 27 2025 | 2025 Q2 | CCRD, EEFT, MAMA, MTRX, PDEX, PESI, QRHC, RELL, RSSS | Cash, Demand Destruction, Microcaps, payments, small caps, Trade Policy, Valuations |
CCRD QRHC CCRD EEFT QRHC |
LCA posted 19% quarterly gains led by CCRD's acquisition, but maintains defensive 10% cash position amid expected demand destruction from trade policies and federal workforce cuts. Manager likes prospects for concentrated holdings MTRX and RSSS but sees market vulnerabilities despite new highs. Continues patient small cap strategy while building cash hedge against policy-driven economic weakness. |
| Jun 5 2025 | 2025 Q1 | CCRD, GOOG, META, MTRX, PDEX, PESI, QRHC, RSSS | Concentration, Long Term, Outperformance, Price Discovery, small caps, value |
CCRD PDEX RSSS MTRX QRHC PESI |
Long Cast delivered 39% returns in 2024, significantly outperforming small cap indices through concentrated investing in undervalued small companies. The manager believes declining analyst coverage creates pricing inefficiencies in small caps. Key holdings include CoreCard, Pro-Dex, and Matrix Services. Portfolio positioned for continued outperformance through patient, long-term value investing approach. |
| Jan 24 2025 | 2024 Q4 | CCRD, MTRX, PDEX, PESI, QRHC, RSSS | Concentration, Industrial, Microcap, Price Discovery, small caps, value |
CCRD PDEX RSSS MTRX QRHC PESI |
Long Cast delivered 39% returns in 2024 through concentrated small cap investing, with top-five positions comprising 70% of assets. Manager exploits market inefficiencies from shrinking analyst coverage, evidenced by delayed price discovery in holdings like CoreCard. Portfolio remains patient and concentrated, adding to existing positions rather than new names while targeting five-year doubles. |
| Oct 25 2024 | 2024 Q3 | AAPL, BANC, CCRD, ENVX, GS, JPM, MTRX, PDEX, PESI, QRHC, SNES | Concentration, Medical Devices, payments, small caps, value |
PDEX CCRD |
Long Cast delivered 6% quarterly returns through concentrated small-cap investing, targeting five-year doubles with 15% position sizes. Medical device manufacturer PDEX contributed meaningfully after capacity expansion. Payment processor CCRD extended its Goldman Sachs agreement through 2030 despite consumer credit headwinds. The manager maintains patient, long-term focus on bottom-up selection over macro predictions. |
| Aug 6 2024 | 2024 Q2 | CCRD, ENVX, MAMA, MTRX, PESI, RELL, RSSS, SOTK | Concentration, Construction, Research, small caps, value |
MTRX RSSS |
Long Cast Advisers posted 1% Q2 returns in their concentrated small-cap strategy, bringing YTD to 10%. The fund maintains focus on under-owned companies with compounding potential. MTRX shows turnaround signs with record backlog while RSSS benefits from strategic acquisitions. No new positions added as existing holdings offer superior IRRs. Top five holdings comprise 68% of portfolio. |
| May 7 2024 | 2024 Q1 | CCRD, CCRN, CTEK, DAIO, ENVX, LRCX, MTRX, PESI, PSSR, QRHC, RELL, RSSS, SNES | concentrated, Cyclical, Fundamental Analysis, small caps, Turnarounds, value | - | Small-cap value manager returned 9% in 1Q24 through concentrated fundamental analysis. Added to top holdings MTRX and CCRD despite near-term headwinds. Portfolio positioned for semiconductor recovery and CCRD earnings inflection. Manager evolved strategy from seeking great companies to identifying stocks capable of doubling in five years through operational change anticipation. |
| Feb 13 2024 | 2023 Q4 | CCRD, MAMA, MTRX, PESI, QRHC, RSSS | - | - | |
| Oct 31 2023 | 2023 Q3 | PDEX, SOTK | - | - | |
| Jun 30 2023 | 2023 Q2 | - | - | - | |
| Aug 5 2023 | 2023 Q1 | MTRX, PESI | - | - | |
| Jan 31 2023 | 2022 Q4 | AMPX, CCRN, ENVX, RSSS | - | - | |
| Oct 10 2022 | 2022 Q3 | CCRN | - | - |
| QUARTER | THEMES | TAGS |
|---|---|---|
| 2025 Q4 |
HealthcareHealthcare was the strongest relative contributor in the quarter with holdings increasing nearly +16% compared to benchmark returns of roughly +12%. Exact Sciences was acquired for a significant premium by Abbott Laboratories resulting in an +86% return, while other strong performers included Tarsus Pharmaceuticals, Glaukos following approval of a new product, Penumbra, and Repligen driven by strong earnings results. |
M&A Product Approval Earnings Biotech |
Small CapsSmall caps getting strong start in 2026 supported by easing monetary conditions and constructive fiscal backdrop. Small caps more sensitive to economic cyclicality which is overdue for expansion. Expected to grow at better pace than large caps in 2026 after long period of underperformance. |
Value Growth Cyclical Monetary Policy Fiscal Policy | |
ValueManager emphasizes investing in controlled companies trading at significant discounts to NAV, with European holding companies showing discounts of 30-68%. The strategy focuses on securities mispricing where real value exists, contrasting with overvalued technology stocks. |
Discounts NAV Mispricing Undervalued Controlled | |
| 2025 Q3 |
Contract ManufacturingFLEX evolved from low-value electronics assembly to high-value specialized manufacturing for medical, industrial, and automotive industries. Under CEO Revathi Advaithi, the company achieved operational discipline and double-digit earnings growth with expanding margins, benefiting from accelerating data center end-markets. |
Manufacturing Data Centers Operational Discipline Margins |
Scientific Publishing |
||
Small CapsSmall caps getting strong start in 2026 supported by easing monetary conditions and constructive fiscal backdrop. Small caps more sensitive to economic cyclicality which is overdue for expansion. Expected to grow at better pace than large caps in 2026 after long period of underperformance. |
Value Growth Cyclical Monetary Policy Fiscal Policy | |
| 2025 Q2 |
PaymentsWise represents the most asymmetric investment in the portfolio, taking market share from legacy correspondent banking through cheaper, faster, and more transparent infrastructure. The company is evolving from a remittance app into a global financial services platform with three reinforcing routes to market: Consumer, Business and Platform. |
Cross-border Fintech Infrastructure Platform SME |
Small CapsSmall caps getting strong start in 2026 supported by easing monetary conditions and constructive fiscal backdrop. Small caps more sensitive to economic cyclicality which is overdue for expansion. Expected to grow at better pace than large caps in 2026 after long period of underperformance. |
Value Growth Cyclical Monetary Policy Fiscal Policy | |
Trade PolicyRecent tariff policies continued to negatively impact U.S. consumers and companies throughout the year. However, international companies have been finding new trade arrangements and growth opportunities, benefiting from shifts in global trade patterns as the new U.S. administration alters terms of international cooperation. |
Tariffs International Growth Cooperation Impact | |
| 2025 Q1 |
Small CapsSmall caps getting strong start in 2026 supported by easing monetary conditions and constructive fiscal backdrop. Small caps more sensitive to economic cyclicality which is overdue for expansion. Expected to grow at better pace than large caps in 2026 after long period of underperformance. |
Value Growth Cyclical Monetary Policy Fiscal Policy |
ValueManager emphasizes investing in controlled companies trading at significant discounts to NAV, with European holding companies showing discounts of 30-68%. The strategy focuses on securities mispricing where real value exists, contrasting with overvalued technology stocks. |
Discounts NAV Mispricing Undervalued Controlled | |
| 2024 Q4 |
Small CapsSmall caps getting strong start in 2026 supported by easing monetary conditions and constructive fiscal backdrop. Small caps more sensitive to economic cyclicality which is overdue for expansion. Expected to grow at better pace than large caps in 2026 after long period of underperformance. |
Value Growth Cyclical Monetary Policy Fiscal Policy |
| 2024 Q3 |
Medical DevicesHoldings include Ceribell for portable EEG technology and Stevanato Group for pharmaceutical packaging. Ceribell surged 91% after FDA clearance for neonatal applications, while Stevanato faced conservative guidance despite beating expectations. |
EEG Technology FDA Clearance Pharmaceutical Packaging Medical Technology Healthcare Innovation |
PaymentsWise represents the most asymmetric investment in the portfolio, taking market share from legacy correspondent banking through cheaper, faster, and more transparent infrastructure. The company is evolving from a remittance app into a global financial services platform with three reinforcing routes to market: Consumer, Business and Platform. |
Cross-border Fintech Infrastructure Platform SME | |
| 2024 Q2 |
Small CapsSmall caps getting strong start in 2026 supported by easing monetary conditions and constructive fiscal backdrop. Small caps more sensitive to economic cyclicality which is overdue for expansion. Expected to grow at better pace than large caps in 2026 after long period of underperformance. |
Value Growth Cyclical Monetary Policy Fiscal Policy |
| 2024 Q1 |
Semiconductor CycleThe portfolio's underweight to South Korean semiconductor companies, including Samsung Electronics and SK Hynix, was a key driver of relative underperformance. These stocks continued to benefit from strong AI-related memory demand and elevated investor enthusiasm. Memory chips are largely a commoditized product with weak pricing power, extreme capital intensity and pronounced boom-bust cycles that lead to volatile earnings. |
Memory South Korea Cyclical Commoditized Volatility |
Small CapsSmall caps getting strong start in 2026 supported by easing monetary conditions and constructive fiscal backdrop. Small caps more sensitive to economic cyclicality which is overdue for expansion. Expected to grow at better pace than large caps in 2026 after long period of underperformance. |
Value Growth Cyclical Monetary Policy Fiscal Policy |
| Date | Pitch Type | Author | Ticker | Company | Industry | Sub Industry | Bull / Bear | Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 24, 2026 | Fund Letters | Avram Fisher | CCRN | Cross Country Healthcare, Inc. | Health Care | Health Care Services | Bull | NASDAQ | balance sheet, healthcare, Margins, Nursestaffing, turnaround | Login |
| Jan 24, 2026 | Fund Letters | Avram Fisher | NRC | NRC Health, Inc. | Health Care | Health Care Technology | Bull | NASDAQ | Deferred revenue, healthcare, Margins, Owner operator, valuation | Login |
| Jan 24, 2026 | Fund Letters | Avram Fisher | MTRX | Matrix Service Company | Industrials | Construction & Engineering | Bull | NASDAQ | backlog, engineering, infrastructure, operating leverage, turnaround | Login |
| Jan 24, 2026 | Fund Letters | Avram Fisher | RSSS | Research Solutions, Inc. | Information Technology | Software | Bull | NASDAQ | contrarian, marketshare, research, Software, Subscriptions | Login |
| Nov 24, 2025 | Fund Letters | Avram Fisher | PDEX | Pro-Dex, Inc. | Health Care | Medical Devices | Bull | NASDAQ | buybacks, Catalysts, EBITDA, Medtech, Oem, robotics, Smallcap, Surgical | Login |
| Nov 24, 2025 | Fund Letters | Avram Fisher | MTRX | Matrix Service Company | Industrials | Engineering & Construction Services | Bull | NASDAQ | construction, Cyclical, EBITDA, energy, infrastructure, rerating, turnaround | Login |
| Nov 24, 2025 | Fund Letters | Avram Fisher | RSSS | Research Solutions, Inc. | Information Technology | Application Software | Bull | NASDAQ | AI, Curation, Data, research, SaaS, Smallcap, Subscriptions | Login |
| Nov 24, 2025 | Fund Letters | Avram Fisher | PESI | Perma-Fix Environmental Services, Inc. | Industrials | Environmental & Facilities Services | Bull | NASDAQ | annuity, ESG, Government, Nuclear, Remediation, specialty, waste | Login |
| Nov 24, 2025 | Fund Letters | Avram Fisher | QRHC | Quest Resource Holding Corporation | Industrials | Environmental & Facilities Services | Bull | NASDAQ | ESG, Impairment, Recycling, services, Smallcap, turnaround, waste | Login |
| Aug 27, 2025 | Fund Letters | Avram Fisher | CCRD | CoreCard Corporation | Information Technology | Data Processing & Outsourced Services | Bull | New York Stock Exchange | acquisition, cross-selling, Fintech, Merger Arbitrage, Payments | Login |
| Aug 27, 2025 | Fund Letters | Avram Fisher | QRHC | Quest Resource Holding Corporation | Industrials | Environmental & Facilities Services | Bull | NASDAQ | Activism, cash flow, microcap, turnaround, waste management | Login |
| Aug 1, 2025 | Fund Letters | Long Cast Advisers | CCRD | CoreCard Corporation | Information Technology | Data Processing & Outsourced Services | Bull | NYSE | acquisition target, Apple Card, Credit Card Processing, digital payments, financial technology, Fintech, Payment Platform | Login |
| Aug 1, 2025 | Fund Letters | Long Cast Advisers | EEFT | Euronet Worldwide Inc | Information Technology | Data Processing & Outsourced Services | Neutral | NASDAQ | ATM Networks, Bank Customers, Credit Card Issuing, cross-selling, founder-led, International Payments, Merchant Acquiring, payment processing | Login |
| Aug 1, 2025 | Fund Letters | Long Cast Advisers | QRHC | Quest Resource Holding Corporation | Industrials | Environmental & Facilities Services | Neutral | NASDAQ | Board Governance, cash flow generation, environmental services, Leverage Issues, Management Change, microcap, turnaround, waste management | Login |
| Jan 1, 2025 | Fund Letters | Long Cast Advisers | CCRD | CoreCard Corporation | Information Technology | Data Processing & Outsourced Services | Bull | NYSE | Apple Card, Contract Extension, credit card services, Data Processing, financial technology, Goldman Sachs, regulatory environment | Login |
| Jan 1, 2025 | Fund Letters | Long Cast Advisers | PDEX | Pro-Dex Inc | Health Care | Health Care Equipment | Bull | NASDAQ | Branded Products, Gross Profit, Healthcare Equipment, manufacturing, Medical devices, Multi-year Contract, Surgical Instruments | Login |
| Jan 1, 2025 | Fund Letters | Long Cast Advisers | RSSS | Research Solutions Inc | Communication Services | Interactive Media & Services | Bull | NASDAQ | Corporate Governance, Founder Exit, Patient Capital, Research Intelligence, SaaS, Stock Overhang, value opportunity | Login |
| Jan 1, 2025 | Fund Letters | Long Cast Advisers | MTRX | Matrix Service Company | Industrials | Construction & Engineering | Bull | NASDAQ | backlog conversion, Cash Flow Inflection, COVID Recovery, Cyclical Recovery, Engineering Construction, Long Cycle, Market Inattention | Login |
| Jan 1, 2025 | Fund Letters | Long Cast Advisers | QRHC | Quest Resource Holding Corporation | Industrials | Environmental & Facilities Services | Neutral | NASDAQ | Customer concentration, EV Policy, Farm Recession, Industrial Headwinds, management communication, Technology Transformation, waste management | Login |
| Jan 1, 2025 | Fund Letters | Long Cast Advisers | PESI | Perma-Fix Environmental Services Inc | Industrials | Environmental & Facilities Services | Bull | NASDAQ | Geographic Monopoly, government contracts, Hanford cleanup, Nuclear Waste, regulatory barriers, Secondary Waste, Vitrification Plant | Login |
| Jan 1, 2025 | Fund Letters | Long Cast Advisers | CCRD | CoreCard Corporation | Information Technology | Data Processing & Outsourced Services | Bull | NYSE | Apple Card, Contract Extension, credit card services, Data Processing, financial technology, Goldman Sachs, regulatory environment | Login |
| Jan 1, 2025 | Fund Letters | Long Cast Advisers | PDEX | Pro-Dex Inc | Health Care | Health Care Equipment | Bull | NASDAQ | Branded Products, capacity expansion, Healthcare Equipment, manufacturing, Medical devices, Multi-year Contract, Surgical Instruments | Login |
| Jan 1, 2025 | Fund Letters | Long Cast Advisers | RSSS | Research Solutions Inc | Communication Services | Interactive Media & Services | Bull | NASDAQ | Corporate Governance, Founder Exit, Patient Capital, Research Intelligence, SaaS, Stock Overhang | Login |
| Jan 1, 2025 | Fund Letters | Long Cast Advisers | MTRX | Matrix Service Company | Industrials | Construction & Engineering | Bull | NASDAQ | backlog conversion, cash flow generation, COVID Recovery, Cyclical Recovery, Engineering Construction, market inefficiency, operating leverage | Login |
| Jan 1, 2025 | Fund Letters | Long Cast Advisers | QRHC | Quest Resource Holding Corporation | Industrials | Environmental & Facilities Services | Neutral | NASDAQ | Customer Additions, EV Policy, Farm Recession, Industrial Headwinds, Recycling Services, Technology Transition, waste management | Login |
| Jan 1, 2025 | Fund Letters | Long Cast Advisers | PESI | Perma-Fix Environmental Services Inc | Industrials | Environmental & Facilities Services | Bull | NASDAQ | environmental services, Geographic Advantage, government contracts, Hanford cleanup, Nuclear Waste, Regulatory Moat, Vitrification Plant | Login |
| Oct 1, 2024 | Fund Letters | Long Cast Advisers | PDEX | Pro-Dex Inc | Health Care Equipment & Services | Health Care Equipment | Bull | NASDAQ | capital-efficient, contract manufacturing, Healthcare Technology, Manufacturing Expansion, Medical Device, Orthopedic, Surgical Instruments | Login |
| Oct 1, 2024 | Fund Letters | Long Cast Advisers | CCRD | CoreCard Corporation | Software & Services | Systems Software | Bull | NYSE | Apple Card, Credit Card Technology, debt-free, Fintech, Goldman Sachs, payment processing, Share Buybacks, Software Licensing | Login |
| Aug 1, 2024 | Fund Letters | Long Cast Advisers | MTRX | Matrix Service Company | Industrials | Construction & Engineering | Bull | NASDAQ | backlog, construction, Cyclical, EBITDA, engineering, Oil & Gas, Petrochemical, seasonality, turnaround, Value | Login |
| Aug 1, 2024 | Fund Letters | Long Cast Advisers | RSSS | Research Solutions Inc | Communication Services | Interactive Media & Services | Bull | NASDAQ | Academic, B2C, Citations, M&A, Management Transition, Overhang, Reference Management, research, SaaS, Software | Login |
| TICKER | COMMENTARY |
|---|---|
| CCRD | For the full year, MAMA, CCRD and PESI led returns. For the year, our largest sales were CCRD and RELL. As you may recall, CCRD was acquired in October and is no longer listed. Cumulative gains on the stock at year-end exceeded $1M. In 2025 we realized ~60% of these gains (mostly long-term) and rolled the remainder into its acquirer, Euronet Worldwide (EEFT). |
| CCRN | Our largest purchases in the quarter were PDEX, CCRN and NRC. We are revisiting the nurse staffing company we first owned back in 2019 and sold when COVID comps turned negative. At $8 / share and with 32M shares out, the company has a $260M market capitalization. At its most recent quarter, the company had $99M in net cash and no debt. In December it received a $20M termination payment following its failed $615M acquisition by AYA. This leaves it with over 40% of its market cap in cash and a pro forma enterprise value of $140M. |
| EEFT | In 2025 we realized ~60% of these gains (mostly long-term) and rolled the remainder into its acquirer, Euronet Worldwide (EEFT). There is a bear market for legacy payments stalwarts like EEFT, but it is profitable and cash generative, trades for a single digit valuation and has several potential growth tailwinds including the benefits from the CCRD purchase that may reward investors over time. |
| LSYN | For the full year, offset by declines in QRHC, RSSS and the unfortunate permanent loss of capital in our small position in LSYN. |
| MAMA | stocks scaling very nicely and entering the small-cap sweet spot (REAL, MAMA, CBLL, KRMD). |
| MTRX | In 4Q25 RSSS and MTRX were the largest detractors. The bear case against MTRX, one of our largest positions, is that despite its historically high backlog, it can't build profitably. And in fact, recent financial results support this view. As discussed in prior letters, one would have to go back to pre-COVID times to understand the earnings power in the business. I believe we are near the inflection where this should become clear. As I wrote in the 3Q25 letter, if they can show profitability, which should come as soon as next quarter, I believe doubters will have to reconsider their thinking and re-rate the multiple, now less than 8x a bad scenario $20M in EBITDA. |
| NRC | Our largest purchases in the quarter were PDEX, CCRN and NRC. Among our meaningful contributors in the quarter, NRC is our newest position. With 23M shares out and a current market price of $19, the company has a $430M market capitalization and including net debt, a roughly $500M enterprise value. At that price, it trades at a 13x multiple against $40M of annualized EBITDA, using the most recent quarter's results of $10M, which I believe to be the trough. |
| PDEX | In 4Q25 MAMA, PESI and PDEX were the biggest contributors to returns. Our largest purchases in the quarter were PDEX, CCRN and NRC. For the year, our largest purchases were PDEX, PESI and NRC. We discussed PDEX at length in our 3Q25 letter. |
| PESI | In 4Q25 MAMA, PESI and PDEX were the biggest contributors to returns. For the full year, MAMA, CCRD and PESI led returns. Given the kinds of cash flows inferred by the volumes expected at Hanford, why shouldn't this be worth +$50? This is really just getting started. |
| QRHC | For the full year, offset by declines in QRHC, RSSS and the unfortunate permanent loss of capital in our small position in LSYN. |
| RELL | For the year, our largest sales were CCRD and RELL. |
| RSSS | In 4Q25 RSSS and MTRX were the largest detractors. For the full year, offset by declines in QRHC, RSSS and the unfortunate permanent loss of capital in our small position in LSYN. The company sells a subscription product on a per seat basis to an industry that faces contraction as a result of the US federal government withdrawing funds from research and science. My divergent view is that I think it can gain share in a shrinking market, while the stock market prices this as if it can't. |
| Ticker | Put/Call | Amount Bought | Shares Bought | % Change | Weight % |
|---|---|---|---|---|---|
| No Recent Buys Data | |||||
| Ticker | Put/Call | Amount Sold | Shares Sold | % Change | Weight % | Status |
|---|---|---|---|---|---|---|
| No Recent Sells Data | ||||||
| Industry | Prev Quarter % | Current Quarter % | Change |
|---|---|---|---|
| No industry data available | |||